Corpus ID: 9091783

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

@article{Stevens1987AntitumorAA,
  title={Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M \& B 39831), a novel drug with potential as an alternative to dacarbazine.},
  author={M. Stevens and J. Hickman and S. Langdon and D. Chubb and L. Vickers and R. Stone and G. Baig and C. Goddard and N. Gibson and J. Slack},
  journal={Cancer research},
  year={1987},
  volume={47 22},
  pages={
          5846-52
        }
}
A number of 3-alkyl analogues of the experimental antitumor drug mitozolomide [8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H )-one] have been screened against murine tumors in vivo. Only the compounds with a 3-methyl- or 3-bromoethyl group possessed significant antitumor activity against the TLX5 lymphoma. The 3-methyl analogue, 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045), was investigated further and found to possess good activity, when… Expand

Paper Mentions

Interventional Clinical Trial
The protocol is designed to determine the efficacy of temozolomide in preventing the development of new brain metastases within the first year in patients undergoing stereotactic… Expand
ConditionsBrain Metastases, Cancer
InterventionDrug
Interventional Clinical Trial
The goal of this study is to evaluate the effects of temozolomide and radiation combination in the treatment intended of soft tissue sarcomas. This study will also look at the… Expand
ConditionsSoft Tissue Sarcomas
InterventionDrug, Procedure, Radiation
Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
...
1
2
3
4
5
...